文献速递银屑病与炎症性皮肤病

银屑病系统治疗的心血管安全性:BIOBADADERM登记前瞻性队列研究

Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-04-30

该研究基于BIOBADADERM登记的前瞻性队列,分析5622例银屑病患者、11368个治疗周期和21762人年的数据,采用倾向评分匹配和泊松回归比较各系统治疗与甲氨蝶呤(MTX)的主要不良心血管事件(MACE)发生率。结果显示阿普米司特(APR)和IL-17抑制剂与MACE风险降低相关,环孢素(CYC)与风险升高相关,其余治疗无显著差异。

要点

  • APR与IL-17抑制剂较MTX显著降低MACE风险。
  • 环孢素较MTX显著增加MACE风险。
  • 其余系统治疗未显示MACE风险显著变化。

核心结论

  • 真实世界证据提示APR和IL-17抑制剂与较低的MACE发生率相关,而CYC与较高的MACE发生率相关。

研究设计与样本

  • 前瞻性队列研究,使用BIOBADADERM登记数据,纳入5622例患者、11368个治疗周期和21762人年。
  • 采用倾向评分匹配调整治疗组基线差异,并以泊松回归模型校正潜在混杂因素。

主要发现

  • APR较MTX的MACE调整发病率比(IRR)为0.17(95%CI 0.04-0.70)。
  • IL-17抑制剂较MTX的MACE调整IRR为0.43(95%CI 0.20-0.91)。
  • 环孢素较MTX的MACE调整IRR为3.59(95%CI 1.17-10.99)。
  • 其余系统治疗(抗TNF、IL-12/23抑制剂、IL-23抑制剂、二甲富马酸酯、阿维A等)与MTX相比MACE风险无显著差异。

关键数值与推荐

  • 主要结局为MTX与其他系统治疗之间MACE的调整发病率比(IRR),报告95%CI。

临床怎么用

  • 选择银屑病系统治疗时需考虑心血管结局,APR和IL-17抑制剂可能具有较低MACE风险。
  • 使用环孢素时应关注MACE风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is a chronic inflammatory disease with multiple comorbidities, including an increased risk of major adverse cardiovascular events (MACE). There is limited and contradictory evidence comparing the impact of systemic treatments for psoriasis on MACE. OBJECTIVES: To evaluate the incidence of MACE associated with each systemic treatment used for patients with psoriasis and compare these rates to those observed with methotrexate (MTX). METHODS: We conducted a prospective cohort study using data from the BIOBADADERM registry. Propensity score matching was used to adjust for baseline differences between treatment groups. We calculated the incidence rate (IR) of MACE for each systemic treatment class, including biologics (anti-TNF, IL-12/23, IL-17 and IL-23 inhibitors), conventional systemic therapies (MTX, cyclosporine, dimethyl fumarate and acitretin) and apremilast (APR). The IR for each group was compared to those observed in patients treated with MTX using Poisson regression models adjusted for potential confounders, with 95% confidence intervals (95% CI). The primary outcome was the adjusted incidence rate ratios (IRR) for MACE between patients receiving MTX and those receiving another systemic treatment. RESULTS: We analysed data from 5622 patients, 11,368 treatment cycles and 21,762 person-years (PYs). APR (IRR = 0.17; 95% CI, 0.04-0.70) and IL-17 (IRR = 0.43; 95% CI, 0.20-0.91) were associated with a significant reduction in the risk of MACE compared to MTX. Cyclosporine was associated with an increased risk of MACE (IRR = 3.59; 95% CI, 1.17-10.99) compared to MTX. The remaining systemic psoriasis treatments were not significantly associated with an increased or decreased risk of MACE. CONCLUSIONS: This real-world evidence study indicates a potential association between APR and IL-17 with a lower incidence of MACE, while CYC showed a higher incidence compared to MTX. These findings underscore the importance of considering cardiovascular outcomes when selecting systemic therapies for patients with psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Lluch-Galcerá JJ, Carrascosa JM, González-Quesada A, et al. Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2025. PMID: 40304106. doi:10.1111/jdv.20705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。